Study of safety, tolerability and efficacy of MK0493 in obese patients
Latest Information Update: 09 May 2022
At a glance
- Drugs MK 0493 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 02 Aug 2007 New trial record.